In a previous study, we 10 addressed ourselves to the question of whether amantadine was effective in the treatment of Parkinson's disease. By qualitative and quantitative criteria, amantadine ( Symmetrel) was found to be a safe and effective agent, with specific improvement occurring in tests involving gait, coordination, strength, and more complex activities of daily living. We here report a comparison of levodopa, amantadine, and the combination of the two in the therapy of parkinsonism, using the same battery of subjective and objective tests of neurologic and neuropsychological function as in the previous study 10 and incorporating an additional battery of tracking tests designed to measure more complex coordinated movements. 
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The original selection method, the tests used, and the principles of test application have been described. 10 A section of the results deals with those patients who did not complete the trial for one reason or another. At the conclusion of the previous trial, each patient was begun on levodopa therapy and amantadine was gradually withdrawn. The dose of levodopa was gradually increased over the following 4 to 5 months, until the patient reached a stable, maximal tolerable dose; that is, the dose was increased by 250 to 500 mg. increments once or twice weekly until each patient developed nausea or other troublesome side effects. When such an effect was encountered, the patient was given the immediately preceding dose, and we waited one week before attempting to increase the dose. The patient was considered to have reached his maintenance dose only after 3 or more unsuccessful attempts were made to exceed the dose which produced the troublesome side effect. The only side effects we considered acceptable were mild nausea and anorexia without weight loss. Each patient had been on levodopa therapy for at least 6 months and had been on maintenance dosage for at least 6 weeks at the time of the first test period. After evaluation on levodopa alone, patients were randomly allocated into two treatment groups, with the use of a double-blind design. One group was given 100 mg. of amantadine twice daily and the other a placebo capsule of identical taste and appearance twice daily. Three weeks later, patients returned for evaluation. An interval history was obtained and neurologic function evaluated. The amantadine and placebo groups were then crossed over. Three weeks later, the patients returned for a final evaluation. Each patient had been evaluated by history and test battery 7 times by the completion of the trial, but only the last 5 evaluations are analyzed in this report.
Evaluations were made: ( 1) on placebo alone, ( 2) on amantadine alone, ( 3) on levodopa alone, ( 4) on levodopa plus placebo, and ( 5) on levodopa plus 
Comparisons of treatment groups (Tables II to VI).
In the second column of each table, tests which were significantly improved with amantadine are indicated by asterisks. In Tables IV to VI, the values are expressed in terms of percentage of normal function. Because of the large number of tests involved in the quantitative evaluation of neurologic function ( QENF), only those tests which were significantly changed at some time during the trial have been listed. The third column of each table indicates comparisons of amantadine and levodopa. In the last two columns, levodopa plus amantadine and levodopa plus placebo are compared.
Amantadine. The results in the 28 patients who completed the entire trial are in agreement with the analysis of all 42 patients previously reported. 10 Seven of 27 neurologic signs, 4 of 6 disability categories, 15 of 42 quantitative tests of neurologic function, and 9 of 19 simulated activities of daily living were significantly better on amantadine than on placebo. The only psychological test which improved was the digit symbol substitution test, which involves fine motor coordination. Because of the extensive analysis in the previous paper, this comparison will not be described further here, but it clearly indicates superiority of amantadine over placebo.
Levodopa versus amantadine. The patients reported greater improvement on levodopa than amantadine in functional disability in 4 of the 6 categories evaluated -dressing, hygiene, feeding, and speech. The neurologists judged a significant overall improvement of tremor in the upper extremities, finger movements of the dominant hand, and associated bodily movements bilaterally. For all the other symptoms and signs evaluated, the two drugs produced indistinguishable benefits. The quantitative tests revealed a more striking superiority of levodopa over amantadine. Twelve of 42 QENF tests showed greater improvement on levodopa, including grip strength, foot speed, foot coordination, and tandem gait. There was also a slight but significant improvement in two-point discrimination. Amantadine and levodopa produced indistinguishable improvement in hand coordination, rotary pursuit, and pencil flipping. Analysis of the more complex and skilled activities of daily living ( SADL) revealed that in 5 of 19 there was significantly better performance on levodopa than on amantadine (use of zipper, cutting utensils, fork, safety pin, opening an envelope). The two drugs produced indistinguishable improvement in use of a small button, tying a bow, squeezing toothpaste, dialing a telephone, drinking from a glass, and scrubbing the hands. If the SADL tests are all combined, levadopa produces an average 23.9 per cent improvement over placebo compared to a 6.4 per cent improvement for amantadine. The improvement in these complex practiced skills is more striking than for the more basic abilities tested by the QENF. Of the nine neuropsychologic tests, two showed significantly better performance on levodopa (digit symbol substitution and object assembly) than amantadine. Both have a motor output. Neither drug produced significant improvement in cogwheeling, speed of rapid alternating movements, speed of foot tapping, leg rigidity, or postural stability with the eyes closed. A slight but significant decrease in grip strength was noted after amantadine, while a similar decrease in deltoid strength was noted after levodopa.
Levodopa plus amantadine. No individual category of functional disability was significantly better on the combination of drugs, but all the scores were lower on the average. If all the disability scores are summed, the combination of levodopa and amantadine was significantly better than levodopa alone.
Scores from the standard neurologic examination reveal that the combination improves arm tremor, leg tremor, and gait more than does levodopa alone. Analysis of the QENF tests reveals that the combi- nation is superior to levodopa alone for the following: dominant hand-grip strength, pencil Hipping, dominant foot-foot coordination and index of performance, nondominant foot-foot speed, foot coordination and index of performance, and tandem gait, supported. Thus, amantadine seems to offer an additional boost in function, especially in terms of coordination in the hands and feet. This was also evident in the timed SADL tests, in which the combination was superior to levodopa alone for zipping, cutting, and opening a door. It is important to note that amantadine produced an incremental improvement averaging 4.9 per cent in these tests, even after the striking improvement by levodopa. There was little further effect on neuropsychological performance with the addition of amantadine, only picture completion being significantly better. However, as the trial progressed, gradual improvement was noted in several other tests, although this was not statistically significant. When the combination of levodopa and amantadine was compared to initial placebo scores, significant improvement was noted for the written symbol digit, digit symbol, object assembly, picture completion, the verbal organization test, and the Raven progressive matrices.
Side effects of amantadine with levadopa. No new side effects were reported. 10 One patient had recurrence of ankle edema which he had experienced when on amantadine in the earlier phase of the trial, and two women noted the return of livedo reticularis when amantadine was restarted. Deaths. Two deaths occurred during the trial. The first patient developed symptoms of congestive heart failure during the first placebo period and this gradually worsened during amantadine and levodopa administration. Heart failure responded poorly to digitalis, diuretics, and the withdrawal of all anti-Parkinson medications, and she eventually died. The second patient had an unreported history of periodic ankle swelling and had previously taken digitalis and diuretics, though he was not taking them on admission to the study. Ankle swelling recurred both times when amantadine was given, and following the completion of the trial he developed orthopnea and paroxysmal nocturnal dyspnea. Amantadine was withdrawn and he seemed to be improving on digoxin and hydrochlorothiazide, when he developed acute urinary retention and suddenly died at home. Pulmonary embolism was suspected, but an autopsy was not permitted. Increased ambulation with consequent increased strain on the heart may have played a role in the precipitation of heart failure in this patient, though the relation of heart failure to amantadine was not clear in the
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